Market research
OXFD Oxford Immunotec Global PLC
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 562M
- P/E ratio
- 11.75
- Analyst target
- 22.5
- Dividend yield
- 0.0%
- Beta
- 1.38
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- GB00BGFBB958
- Market cap
- 562M
- P/E ratio
- 11.75
- Analyst target
- 22.5
- Dividend yield
- 0.0%
- Beta
- 1.38
About
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OXFD discussion.
5 years, 4 months ago
Oxford Immunotec Global PLC is currently in a long term uptrend where the price is trading 33.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.0.
Oxford Immunotec Global PLC's total revenue sank by 8.4% to $19M since the same quarter in the previous year.
Its net income has dropped by 120.8% to $-149K since the same quarter in the previous year.
Finally, its free cash flow fell by 867.2% to $-5M since the same quarter in the previous year.
Based on the above factors, Oxford Immunotec Global PLC gets an overall score of 2/5.